Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - etinilestradiol, gestoden - tableta - etinilestradiol 0,03 mg / 1 tableta; gestoden 0,075 mg / 1 tableta - gestoden in etinilestradiol

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - etinilestradiol; gestoden - tableta - etinilestradiol 0,02 mg / 1 tableta  gestoden0,075 mg / 1 tableta; gestoden 0,075 mg / 1 tableta - gestoden in etinilestradiol

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - etinilestradiol; gestoden - tableta - etinilestradiol 0,03 mg / 1 tableta  gestoden0,075 mg / 1 tableta; gestoden 0,075 mg / 1 tableta - gestoden in etinilestradiol

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - drospirenon; etinilestradiol - filmsko obložena tableta - drospirenon 3 mg / 1 tableta  etinilestradiol0,02 mg / 1 tableta; etinilestradiol 0,02 mg / 1 tableta - drospirenon in etinilestradiol

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

etinilestradiol; etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 2,7 mg / 1 sistem  etinilestradiol2,7 mg / 1 sistem  etonogestrel11,7 mg / 1 sistem; etinilestradiol 2,7 mg / 1 sistem  etonogestrel11,7 mg / 1 sistem; etonogestrel 11,7 mg / 1 sistem - vaginalni obroček s progestogenom in estrogenom

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sanolabor, d.d. - holestiramin - prašek za peroralno suspenzijo - holestiramin 4 g / 1 g - holestiramin

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - holestiramin - prašek za peroralno suspenzijo - holestiramin 4 g / 1 vreča - holestiramin

Европейски съюз - словенски - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hidroklorid - kolorektalne neoplazme - antineoplastična sredstva - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Европейски съюз - словенски - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - pankreatične neoplazme - antineoplastična sredstva - zdravljenje metastatskega adenokarcinoma trebušne slinavke, v kombinaciji z 5 flúorouracíl (5-fu) in leucovorin (lv), pri odraslih bolnikih, ki so napredovali po gemcitabin na zdravljenje.

Европейски съюз - словенски - EMA (European Medicines Agency)

les laboratoires servier - pixantrone dimaleate - limfom, non-hodgkin - antineoplastična sredstva - zdravilo pixuvri je indicirano kot monoterapija za zdravljenje odraslih bolnikov z multiplo relapsnimi ali neodzivnimi agresivnimi limfomi brez hodgkinov b celic (nhl). prednost piksantona pri bolnikih, ki se uporabljajo kot pete ali večje kemoterapije pri bolnikih, ki so odporni na zadnjo terapijo.